生产厂家英文名：SANOFI U.S. LLC
原产地英文商品名：CLOLAR VIAL 20ML SINGLE DS
最常见的不良反应(10%)：恶心，呕吐，腹泻，发热性胃痛，头痛，皮疹，瘙痒，发热，疲劳，手掌 – 植物性心律失常综合症，焦虑，潮红和粘膜炎症。
Clolar(氯法拉滨)注射液在一次性燧石小瓶中提供，该小瓶含有20mg氯法拉滨20mL溶液。 每个盒子包含一个Clolar小瓶(NDC 0024-5860-01。)20mL flintvials含有20mL(20mg)溶液。溶液的pH范围为4.5至7.5。含有未稀释的Clolar的小瓶应储存在25°C(77°F); 短途旅行允许15至30°C(59 – 86°F)。稀释的外加剂可以在室温下储存，但必须在制备后24小时内使用。应使用适当处理和处置的程序。 Clolars的处理和处置应符合细胞毒性药物的指导原则。 关于这一主题的若干指导方针已经出版。
PrefaceClolaris the brand name of the medication Clofarabine, a medicine used to treat cancer. Clolar is currently indicated to treat acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years old that has relapsed after at least two prior treatments. This is the only indication of Clolar, and it cannot be used for treatment of new ALL cases and for other types of cancer. Clolar is indicated for pediatric refractory ALL based on its response rate alone and there were no trials showing that it can extend survival or improve disease-related symptoms.Acute lymphoblastic leukemia is a type of blood and bone marrow cancer. ALL happens when too many stem cells from the bone marrow becomes lymphoblasts (hence, the term ‘lymphoblastic’), B lymphocytes and T lymphocytes. These cells are not normal, and not able to hunt and fight infectious pathogens well. Also, the sudden drastic increase of these cells create less room for red blood cells, white blood cells and platelets, reducing their number and causing hallmark symptoms like anaemia, frequent infections and bleeding tendencies. The huge numbers of useless, cancerous cells spreads in via bloodstream and lymph vessels to lymph nodes and other organs to cause complications. ALL is termed ‘acute’ because it progresses fairly quickly in short amount of time and can cause death in a few months. ALL is the most common form of blood cancer in children. When treated early, ALL treatment can be successful. If ALL recurs or relapses after one or two treatments, it is already considered a refractory case because it does not respond to usual medications. Only medicines like Clolar are found to cause good response to refractory cases of ALL.Clolar is manufactured and owned by Genzyme Corporation, a biotechnology company based in Cambridge, Massachusetts which is now a fully owned subsidiary of the French-owned Sanofi S.A. Clolar first entered the market after receiving approval from the United States Food and Drug Administration (FDA) on December 2004. Clolar is classified as an orphan medication and thus not widely available in most pharmacies, even in countries where it is approved.CANCER TREATMENT MEDS dispenses Clolar and delivers it to customers on a prescription-only basis. We are a premier internet pharmacy specializing on orphan medicines such as Clolar, and we deliver to most countries. We are your best source of Clolar; order it now at CANCER TREATMENT MEDS!There is no information indicating the use of Clolar for sarcomas. Clolar is exclusively indicated to treat pediatric cases of refractory ALL. There is no research study or clinical trials supporting the use of Clolar for sarcoma-type cancers or for soft-tissue sarcoma. There is also no documented off-label use of Clolar to treat sarcomas.Clolar medication and useClolar medication is used to treat ALL cases in persons below 21 years old that has recurred despite two previous treatments. Pediatric cases of ALL are usually treated with chemotherapy, radiotherapy or a combination of the two. In case of remission, high-dose treatment of chemotherapy with radiotherapy plus stem cell support is indicated to improve chances of cure or prolong remission. If despite second treatment there is still another remission of ALL, Clolar can now be considered to be used for treatment.Clolar is supplied in a single-use vial containing 20 mg of Clofarabine dissolved in 20 mL 0.9% sodium chloride injection, USP. The recommended dosage of Clolar is 52 mg/m2 of patient’s body surface area, which will be computed by your oncologist.To administer, Clolar must be first filtered through a sterile 0.2 micron syringe filter, then diluted to intravenous fluids 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP prior to infusion to achieve final concentration between 0.15 mg/mL and 0.4 mg/mL. Diluted Clolar must be used within 24 hours, and stored at room temperatures 15 C- 30 C. Your doctor or nurse will prepare Clolar for you. Clolar must be infused through an exclusive intravenous line; no other medicines must be infused in this line to prevent drug incompatibilities.Clolar infusions are given for over 2 hours for 5 consecutive days. Then a waiting period of 2 to 5 weeks is initiated until organ function tests results return to baseline, and Clolar is infused again. During Clolar infusion days, your kidney, heart and liver functions are closely monitored and supportive care such as intravenous fluids and antihyperuremic treatmentare provided. If your creatinine clearance is goes down to between 30 – 60 mg/minute, Clolar dosage is reduced by 50%.Furthermore, additional medications such as anti-emetics and prophylactic steroids are given during Clolar infusions.Clolar dosage may be adjusted if the following toxicities occur:•For grade 3 neutropenia lasting ≥ 4 weeks, Clolar dose is reduced by 25% for the next cycle•Clolar dose is withheld if the patient develops significant infection, which is then restarted when it subsides•Withhold Clolar dose in any event of Grade 3 non-infectious non-hematological toxicity, but not including momentary elevations in serum transaminase and/or bilirubin, and nausea and vomiting controlled by antiemetic therapy. When these toxicities subside, re-administer Clolar with 25% dose reduction•If there is any event of Grade 4 non-infectious non-hematological toxicity, discontinue Clolar administration•If systemic inflammatory response syndrome (SIRS) occur or capillary leak occurs, discontinue Clolar administration•If there is Grade 3 or higher creatinine and bilirubin increases, discontinue Clolar administration. If organ functions returns to baseline and becomes stable, re-administer Clolar at the next scheduled dose with a 25% dose reductionClolar chemical structureClolar has a chemical structure formula C10H11ClFN5O3 and molecular weight of 303.677 g/mol.Clolar, in its vial, appears as a clear and colourless liquid.Clolar in vials is sterile and preservative-free, and therefore can only be used once.According to a study involving 40 ALL patients aged 2 to 19 years of age, Clolar is 47% bound to plasma proteins and concentrations were seen over wide range of body surface areas. Clolar has a half-life of 2.5 hours in the body, and 49-60% of it is excreted in the urine unchanged. The pathways of Clolar to the hepatic (liver) system are not yet known.Clolar definitionClolar is the brand name of the medication Clofarabine. Clofarabine is a medication indicated to treat pediatric cases of recurrent or refractory ALL.Clolar classificationClolar is classified as an antineoplastic medication working as a purine nucleoside metabolic inhibitor indicated for treatment of ALL.